Evolva starts Phase I Clinical Trials on EV-077
Evolva SA announced it has started Phase I clinical trials with its drug candidate EV-077-3201-2TBS. The first-in-man study, a single ascending dose study, will enroll 56 healthy male volunteers and will be conducted in Germany over the next 12 weeks. The purpose of the study is to assess the safety and tolerability of EV-077-3201-2TBS and evaluate its pharmacokinetic profile and pharmacodynamic effects.
Dr. Alexandra Santana Sorensen, VP R&D of Evolva said: “We are very pleased and excited to have reached a significant Milestone by entering Phase I studies with our first drug candidate. We believe that EV-077-3201-2TBS has a very interesting potential in a number of cardiovascular and renal indications.”
EV-077-3201-2TBS is a new chemical entity, with a different mode of action from existing drugs that are being developed for cardiovascular and renal indications.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.